Novartis Pharmaceuticals
East Hanover, New Jersey, 07936, United States
NCT Number: NCT06632730
An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).
Looking for future studies?
Notify MeUp to 14 year
All sexes
Observational
East Hanover, New Jersey, 07936, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 12 months
Medical visits included:
Time frame: Up to 12 months
Medical tests included:
Time frame: Up to 12 months
Treatments included:
Time frame: Baseline
Sociodemographics included:
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Clinical characteristics included:
Time frame: Baseline
Time frame: Baseline
Time intervals included:
Time frame: Baseline
ICD codes included:
Time frame: Baseline
Diagnosis types included:
Time frame: Baseline
Mutations included:
Time frame: Baseline
SMN2 copy numbers: 0, 1, 2, 3, 4, and greater than 4.
Time frame: Baseline
SMA-associated comorbidities included:
Time frame: Baseline
Family history categories included:
Time frame: Baseline
Types of ventilatory support included:
Time frame: Baseline
Reasons of ventilatory support included:
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Types of administration included:
Time frame: Baseline
Types of nutritional supplementation included liquid thickeners (corn starch and Nutilis Clear thickener, neutral taste, Nutricia) and nutrition supplements (Resource shakes, High protein shakes, Ensure Junior drink, Infatrini, Pediasure Complete, RESOURCE C, Vitamin D, Fortini high protein shakes, protein shakes, Pediasure, Resource with fiber, Resource protein).
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Types of surgeries included:
Time frame: Baseline
Types of joint contractures included proximal and distal.
Time frame: Baseline
Developmental Milestones:
Time frame: Baseline
Surgeries included:
Time frame: Up to 12 months
Healthcare visits included:
Time frame: Up to 12 months
Time frame: Up to 12 months
SMA-related medical visits included:
Time frame: Up to 12 months
SMA-related emergency room visits included outpatient and hospital visits.
Time frame: Up to 12 months
SMA-related hospitalizations included visits to day hospital, admissions to ward, intensive care unit admissions.
Time frame: Up to 12 months
Hospitalization included admission to ward. Reason for hospitalization included related to treatment and not related to treatment.
Time frame: Up to 12 months
Reason for admission to ICU included related to treatment and not related to treatment.
Time frame: Up to 12 months
Time frame: Up to 12 months
Medical areas included:
Time frame: Up to 12 months
Additional tests included:
Time frame: Up to 12 months
Additional tests included:
Time frame: Up to 12 months
Time frame: Up to 6 years and 4 months
Treatments included:
Time frame: Up to 6 years and 4 months
Nusinersen doses included loading and maintenance doses.
Time frame: Up to 6 years and 4 months
Risdiplam dose included starting dose and dose changes.
Time frame: Up to 6 years and 4 months
Time frame: Up to 6 years and 4 months
Time frame: Up to 6 years and 4 months
Novartis
Industry
Therapeutic Management and Current Situation Related to the Use of Resources and Costs of Spinal Muscular Atrophy (SMA) in Spain: A Retrospective, Multicenter Analysis Based on Medical Record Review. TREaSURE Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05715749
Behavior, Central Nervous System Diseases
Columbus, Ohio, United States
View Trial DetailsNCT04042025
Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Palo Alto, California, United States
View Trial DetailsNCT03837184
Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Tokyo, Japan
View Trial DetailsNCT06864767
Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Istanbul, Turkey (Türkiye)
View Trial Details